Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.
Antineoplastic Agents
/ therapeutic use
COVID-19
/ complications
Chemoradiotherapy
/ methods
Clinical Trials as Topic
/ methods
Humans
Mutation
Neoadjuvant Therapy
/ methods
Neoplasm Metastasis
Pandemics
Pulmonary Medicine
/ methods
Risk Factors
Risk Reduction Behavior
SARS-CoV-2
Thoracic Neoplasms
/ epidemiology
Thoracic Surgical Procedures
/ methods
Journal
Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
13
04
2020
revised:
11
05
2020
accepted:
17
05
2020
pubmed:
22
6
2020
medline:
15
12
2020
entrez:
22
6
2020
Statut:
ppublish
Résumé
The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.
Identifiants
pubmed: 32563968
pii: S2590-0412(20)30024-6
doi: 10.1016/j.resmer.2020.100769
pmc: PMC7246014
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
100769Informations de copyright
Copyright © 2020. Published by Elsevier Masson SAS.
Références
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
Cancer Chemother Pharmacol. 2019 Dec;84(6):1153-1155
pubmed: 31630223
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Lancet. 2011 Sep 17;378(9796):1079-88
pubmed: 21831418
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738